AI Article Synopsis
- The study investigated potential clinical biomarkers to assess the effectiveness of nivolumab treatment in advanced gastric cancer (AGC), focusing on Glasgow Prognostic Score (GPS) and disease control by chemotherapy (DCBC) prior to nivolumab.
- The research involved 80 AGC patients receiving nivolumab and found that a GPS of 2 was linked to shorter overall survival, while a successful DCBC was linked to longer progression-free survival.
- The results suggest that GPS and DCBC could serve as valuable biomarkers for nivolumab treatment in AGC, indicating the need for further research to validate these findings.
Article Abstract
Background/aim: This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) of which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), which reflects systemic inflammatory and nutritional status as well as disease control by chemotherapy immediately before nivolumab (DCBC).
Patients And Methods: AGC patients with measurable lesions who were treated with nivolumab in the third- or later-line were included. DCBC was defined as a best overall response of complete response (CR), partial response, stable disease, or non-CR/non-progressive disease achieved by chemotherapy immediately before nivolumab.
Results: Eighty patients were analyzed. Among the various clinical factors, multivariable analysis revealed that a GPS of 2 was significantly associated with a shorter overall survival and DCBC was significantly associated with a longer progression-free survival.
Conclusion: We present the potential of GPS and DCBC as efficient biomarkers of nivolumab for AGC, that warrants further evaluation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439859 | PMC |
| http://dx.doi.org/10.21873/invivo.11989 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!